BOSTON, April 28, 2025--nChroma Bio ("nChroma"), a genetic medicines company advancing programmable in vivo delivery to overcome the limitations of existing therapies, today announced the acceptance ...

WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- ElevateBio, a technology-driven company focused on powering the creation of life-transforming genetic medicines, today announced presentations at the ...

Be Biopharma, Inc. ("Be Bio"), a clinical-stage company pioneering the discovery and development of engineered B Cell Medicines (BCMs), today announced that it will present at the American Society of ...

Additional information, including the accepted abstracts, can be accessed on the ASGCT 28th Annual Meeting website. Presentation materials will be made available in the Science section under ...

We are excited to share our progress advancing our next-generation ADC pipeline at AACR,” said Jane Chung, Sutro’s Chief Executive Officer. “In preclinical studies, STRO-004 consistently demonstrated ...

The dropshipping business model is low-risk and lets you sell products online without managing inventory or shipping.

The Undergraduate Research Symposium was held on Thursday at the Illini Union displaying research by students from all disciplines.

Attivare’s ATTimmune platform technology employs a biomaterial scaffold to establish a new physical microenvironment within ...

Alpha Cognition Inc. (NASDAQ: ACOG) (the "Company" or "Alpha Cognition") today announced three upcoming presentations at the 2025 Alzheimer's Association International Conference (the "AAIC"), taking ...

Six abstracts accepted for presentation includes post hoc analyses and real-world evidence for ZYMFENTRA® (infliximab-dyyb) Findings reinforce clinical decision-making in long-term management of ...

Padeliporfin VTP (brand name Tookad) has previously been approved by the European Union, Israel, and Mexico as a treatment for low-risk prostate cancer, following demonstration of significant clinical ...

Schrödinger, Inc. (Nasdaq: SDGR) presented preclinical data on SGR-3515, its investigational Wee1/Myt1 co-inhibitor today at ...